Par Drugs And Chemicals Limited has informed the Exchange regarding Board meeting held on May 08, 2025.
PAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Par Drugs and Chemicals approved audited financial results for Q4 FY25 and full year FY25. Full year revenue from operations rose modestly to ₹10,097.35 lakhs (from ₹9,564.04 lakhs in FY24), but profit after tax fell to ₹1,335.79 lakhs (from ₹1,450.10 lakhs), with EPS at ₹10.86 (vs ₹11.78). Q4 standalone revenue was ₹2,232.99 lakhs with PAT of ₹165.10 lakhs. The auditor (Sarupria Somani & Associates) gave an unmodified opinion. Critically, the auditor flagged a Key Audit Matter around going concern, noting that the Board approved a slump sale of the company's primary business unit, which contributed over 99% of revenue, and the company plans to pivot into clean energy, real estate, and capital markets. Total assets stood at ₹11,939.01 lakhs with cash of ₹2,757.72 lakhs. The Board also approved ₹23.79 lakh in employee bonus, corporate banking with ICICI, and reviewed policies and governance items. No investor complaints were pending.
The headline results show mild revenue growth but profit decline. Far more significant is the auditor-flagged slump sale of the 99%+ revenue-generating API business and the pivot into clean energy, real estate, and capital markets — a major strategic restructuring that changes the company's core identity and carries execution and going-concern risk for shareholders. Investors should closely follow disclosures on the slump sale terms and use of proceeds before drawing conclusions on future earnings power.